NASDAQ:AKAO Achaogen (AKAO) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free AKAO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.11▼$0.1152-Week Range N/AVolumeN/AAverage Volume3.34 million shsMarket Capitalization$7.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Achaogen alerts: Email Address Ad Gold Safe ExchangeGold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Achaogen Stock (NASDAQ:AKAO)Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.Read More Ad Gold Safe ExchangeGold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! AKAO Stock News HeadlinesFebruary 21, 2024 | benzinga.comRavi Viswanathan's Net WorthDecember 28, 2023 | bbc.comCOP28: Climate mums make themselves heard in halls of powerMay 9, 2024 | Weiss Ratings (Ad)The ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …October 25, 2023 | investing.comAKAOQ Historical DataJuly 28, 2022 | finance.yahoo.comSepterna Strengthens Leadership Team to Advance Novel Small Molecule GPCR Medicines - Yahoo FinanceJune 13, 2022 | nj.comAn N.J. medical expert warns of the rise of superbugs | Opinion - NJ.comApril 28, 2022 | streetinsider.comFlare Therapeutics Appoints Adrian Jubb as Chief Medical Officer - StreetInsider.comApril 26, 2022 | finance.yahoo.comFlare Therapeutics Appoints Adrian Jubb as Chief Medical Officer - Yahoo FinanceMay 9, 2024 | Weiss Ratings (Ad)The ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …April 13, 2022 | law360.comCipla Calls Achaogen Claims Over Lost Ch. 11 Sales 'Weak' - Law360April 13, 2022 | ft.comGreater access to antibiotics is essential for curbing drug resistance - Financial TimesApril 4, 2022 | bizjournals.comLife sciences VC 5AM Ventures adds 2 new funds totaling $750M - San Francisco Business Times - The Business JournalsMarch 19, 2022 | thetimes.co.ukShortage of new antibiotics stokes fears of a 'silent pandemic' - The TimesFebruary 14, 2022 | forbes.comForever In Love And In Love With Forever: Introducing The World's First True Longevity Couple - ForbesFebruary 2, 2022 | globenewswire.comGlobal Urinary Tract Infection Therapeutics Market Size Will Touch USD 11652 Million Mark by 2027, at a 4.56% CAGR - GlobeNewswireJanuary 27, 2022 | finance.yahoo.comApplied Molecular Transport Announces Board Appointments - Yahoo FinanceNovember 25, 2021 | fortune.comTo avoid the superbug pandemic, we must fix the business model for new antibiotics - FortuneNovember 4, 2021 | businesswire.comGlobal Antibiotic Resistance Markets, 2019-2020 & 2021-2027 - Focus on Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination Therapies - ResearchAndMarkets.com - Business WireOctober 8, 2021 | law360.comThe Top In-House Hires Of September - Law360September 27, 2021 | businesswire.comGlobal $13.8 Billion Antimicrobial Resistance Market, 2027 | Opportunity Breakdown by Disease, Pathogen, Drug Class, End-user and Region - ResearchAndMarkets.com - Business WireSeptember 16, 2021 | prnewswire.comGlobal Antibody Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021 - PRNewswireSeptember 15, 2021 | seekingalpha.comContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market - Seeking AlphaSeptember 9, 2021 | law360.comCRISPR Biotech Co. Mammoth Hires Sangamo Atty As GC - Law360August 26, 2021 | bizjournals.comBiotech Dice led by Kevin Judice rolls toward $100M IPO - San Francisco Business Times - San Francisco Business TimesAugust 9, 2021 | businesswire.comCarbapenem-Resistant Enterobacteriaceae Infection Market Insight, Epidemiology and Market Forecast Report 2021-2030 - ResearchAndMarkets.com - Business WireSee More Headlines Receive AKAO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achaogen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2018Today5/09/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:AKAO CUSIPN/A CIK1301501 Webwww.achaogen.com Phone650-800-3636FaxN/AEmployees206Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-186,510,000.00 Net Margins-2,136.94% Pretax MarginN/A Return on Equity-357.49% Return on Assets-127.68% Debt Debt-to-Equity Ratio1.00 Current Ratio0.78 Quick Ratio0.77 Sales & Book Value Annual Sales$8.73 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.13) per share Price / BookN/AMiscellaneous Outstanding Shares63,880,000Free FloatN/AMarket Cap$7.03 million OptionableOptionable Beta0.78 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Blake Wise (Age 48)CEO & Director Mr. Gary Loeb (Age 49)Gen. Counsel, Corp. Sec. & Chief Compliance Officer Ms. Zeryn Sarpangal (Age 39)CFO and Principal Financial & Accounting Officer Ms. Elizabeth Bhatt (Age 50)Chief Bus. Officer & COO Ms. Jeannie LloydsVP of SalesKey CompetitorsiBioNYSE:IBIOShuttle PharmaceuticalsNASDAQ:SHPHTransCode TherapeuticsNASDAQ:RNAZProcessa PharmaceuticalsNASDAQ:PCSATenax TherapeuticsNASDAQ:TENXView All Competitors AKAO Stock Analysis - Frequently Asked Questions How were Achaogen's earnings last quarter? Achaogen Inc (NASDAQ:AKAO) posted its earnings results on Monday, August, 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.92) by $0.19. The biopharmaceutical company earned $2.56 million during the quarter, compared to analysts' expectations of $1.49 million. Achaogen had a negative net margin of 2,136.94% and a negative trailing twelve-month return on equity of 357.49%. What other stocks do shareholders of Achaogen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Achaogen investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Associated British Foods (ABF), Chaarat Gold (CGH), AMC Entertainment (AMC), First Data (FDC), Ciena (CIEN), Cypress Semiconductor (CY) and Synergy Pharmaceuticals (SGYP). This page (NASDAQ:AKAO) was last updated on 5/9/2024 by MarketBeat.com Staff From Our Partners1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achaogen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.